Cite
HARVARD Citation
Lin, C. et al. (2022). First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis. Journal of immunotherapy. 45 (9), pp. 407-414. [Online].